{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T21:57:28Z","timestamp":1648936648589},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10354-016-0480-z","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T09:16:33Z","timestamp":1467710193000},"page":"312-319","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medikament\u00f6se Behandlung chronischer Venenerkrankungen"],"prefix":"10.1007","volume":"166","author":[{"given":"Milo\u0161 D.","family":"Pavlovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"key":"480_CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejvs.2010.09.025","volume":"41","author":"M Perrin","year":"2011","unstructured":"Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results\u00a0and\u00a0unanswered\u00a0questions. Eur J Vasc Endovasc Surg. 2011;41:117\u201325.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"480_CR2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/CIRCGENETICS.112.963439","volume":"5","author":"MA Anwar","year":"2012","unstructured":"Anwar MA, Georgiadis KA, Shalhoub J, et\u00a0al. A\u00a0review\u00a0of\u00a0familial,\u00a0genetic, and congenital aspects of primary varicose vein disease. Circ Cardiovasc Genet. 2012;5:460\u20136.","journal-title":"Circ Cardiovasc Genet"},{"key":"480_CR3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/bjs.6798","volume":"96","author":"C Lim","year":"2009","unstructured":"Lim C, Davies A. Pathogenesis of primary varicose veins. Br J Surg. 2009;96:1231\u201342.","journal-title":"Br J Surg"},{"key":"480_CR4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2125.2001.00334.x","volume":"51","author":"F Brunner","year":"2001","unstructured":"Brunner F, Hoffmann C, Schuller-Petrovi\u0107 S. Responsiveness of human varicose saphenous veins\u00a0to\u00a0vasoactive\u00a0agents. Br J Clin Pharmacol. 2001;51:219\u201324.","journal-title":"Br J Clin Pharmacol"},{"key":"480_CR5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0268355513477282","volume":"28","author":"E Rabe","year":"2013","unstructured":"Rabe E, Guex JJ, Morrison N, et\u00a0al. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013;28:308\u201319.","journal-title":"Phlebology"},{"key":"480_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/lrb.2005.3.81","volume":"3","author":"N Farinola","year":"2005","unstructured":"Farinola N, Piller N. Pharmacogenomics \u2013 its role in re-establishing coumarin as\u00a0treatment\u00a0for lymphedema. Lymphat Res Biol. 2005;3:81\u20136.","journal-title":"Lymphat Res Biol"},{"key":"480_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14756360601073914","volume":"22","author":"D Hadjipavlou-Litina","year":"2007","unstructured":"Hadjipavlou-Litina D, Kontogiorgis C, Pontiki E, et al. Anti-inflammatory and antioxidant activity of coumarins designed as potential fluorescent zinc sensors. J Enzyme Inhib Med Chem. 2007;22:287\u201392.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"480_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1747-0285.2011.01120.x","volume":"77","author":"SH Cardoso","year":"2011","unstructured":"Cardoso SH, Barreto MB, Lourenco MC, et\u00a0al. Antitubercular activity of new coumarins. Chem Biol Drug Des. 2011;77:489\u201393.","journal-title":"Chem Biol Drug Des"},{"key":"480_CR9","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1016\/j.bmcl.2006.06.007","volume":"16","author":"S Lee","year":"2006","unstructured":"Lee S, Sivakumar K, Shin WS, et\u00a0al. Synthesis and antiangiogenesis activity of coumarin derivatives. Bioor Med Chem Lett. 2006;16:4596\u20139.","journal-title":"Bioor Med Chem Lett"},{"key":"480_CR10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12039-011-0147-7","volume":"124","author":"S Gupta","year":"2012","unstructured":"Gupta S, Singh S, Kathuria A, et\u00a0al. Ammonium derivatives of chromenones and quinolinones as lead antimicrobial agents. J\u00a0Chem Sci. 2012;124:437\u201349.","journal-title":"J Chem Sci"},{"key":"480_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cbi.2014.04.015","volume":"218","author":"MH Lin","year":"2014","unstructured":"Lin MH, Cheng CH, Chen KC, et al. Induction of ROS-independent JNK-activation-mediated apoptosis by a novel coumarin-derivative, DMAC, in human colon cancer cells. Chem Biol Interact. 2014;218:42\u20139.","journal-title":"Chem Biol Interact"},{"key":"480_CR12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJM199310143291604","volume":"329","author":"JR Casley-Smith","year":"1993","unstructured":"Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med. 1993;329:1158\u201363.","journal-title":"N Engl J Med"},{"key":"480_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/bmj.307.6911.1037","volume":"307","author":"JR Casley-Smith","year":"1993","unstructured":"Casley-Smith JR, Wang CT, Casley-Smith JR, et al. Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin). BMJ. 1993;307:1037\u201341.","journal-title":"BMJ"},{"key":"480_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1024\/0301-1526.31.3.185","volume":"31","author":"W Vanscheidt","year":"2002","unstructured":"Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of a\u00a0coumarin-\/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa. 2002;31:185\u201390.","journal-title":"Vasa"},{"key":"480_CR15","first-page":"CD003140","volume":"2","author":"C Badger","year":"2004","unstructured":"Badger C, Preston N, Seers K, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;2:CD003140.","journal-title":"Cochrane Database Syst Rev"},{"key":"480_CR16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1111\/j.1476-5381.1995.tb17217.x","volume":"116","author":"T Kinonen","year":"1995","unstructured":"Kinonen T, Pasanen M, Gynther J, et al. Competitive inhibition of\u00a0coumarin\u00a07-hydroxylation by pilocarpine and its interaction with mouseCYP\u00a02A5 and human\u00a0CYP\u00a02A6. Br J\u00a0Pharmacol. 1995;116:2625\u201330.","journal-title":"Br J Pharmacol"},{"key":"480_CR17","doi-asserted-by":"crossref","first-page":"11679","DOI":"10.3390\/molecules190811679","volume":"19","author":"TN Chinembiri","year":"2014","unstructured":"Chinembiri TN, du Plessis LH, Gerber M, et\u00a0al. Review\u00a0of Natural Compounds for Potential Skin Cancer Treatment. Molecules. 2014;19:11679\u2013721.","journal-title":"Molecules"},{"key":"480_CR18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jvs.2011.01.043","volume":"54","author":"JD Raffetto","year":"2011","unstructured":"Raffetto JD, Khalil RA. Ca2+-dependent contraction by the saponoside escin in rat vena cava: Implications in venotonic treatment of varicose veins . J Vasc Surg. 2011;54:489\u201396.","journal-title":"J Vasc Surg"},{"key":"480_CR19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jvs.2012.02.067","volume":"56","author":"CS Lim","year":"2012","unstructured":"Lim CS, Kiriakidis S, Paleolog EM, et al. The effects of doxycycline and micronized purified flavonoid fraction on human vein wall remodeling are not hypoxia-inducible factor pathway-dependent. J Vasc Surg. 2012;56:1069\u201377.","journal-title":"J Vasc Surg"},{"key":"480_CR20","first-page":"310","volume":"31","author":"FA Allaert","year":"2012","unstructured":"Allaert FA. Meta-analysis\u00a0of the\u00a0impact\u00a0of the principal venoactive drugs agents on malleolar\u00a0venous\u00a0edema. Int Angiol. 2012;31:310\u20135.","journal-title":"Int Angiol"},{"issue":"5","key":"480_CR21","doi-asserted-by":"publisher","first-page":"CD006477","DOI":"10.1002\/14651858.CD006477.pub2","volume":"31","author":"C Scallon","year":"2013","unstructured":"Scallon C, Bell-Syer SE, Aziz Z. Flavonoids\u00a0for\u00a0treating\u00a0venous\u00a0leg ulcers. Cochrane Database Syst Rev. 2013;31(5):CD006477 doi:10.1002\/14651858.CD006477.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"480_CR22","unstructured":"Ippolito E, Belcaro G, Dugall M, et\u00a0al. Venoruton\u00ae: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton\u00ae. A five-year, open-registry, efficacy study. Panminerva Med 2011; 53(3 Suppl 1): 13\u20139."},{"key":"480_CR23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ptr.5019","volume":"28","author":"OP Gulati","year":"2014","unstructured":"Gulati, OP. Pycnogenol\u00ae in chronic\u00a0venous\u00a0insufficiency and related venous disorders. Phytother Res. 2014;28:348\u201362.","journal-title":"Phytother Res"},{"issue":"4","key":"480_CR24","doi-asserted-by":"publisher","first-page":"CD008294","DOI":"10.1002\/14651858.CD008294.pub4","volume":"18","author":"A Schoonees","year":"2012","unstructured":"Schoonees A, Visser J, Musekiwa A, et\u00a0al. Pycnogenol\u00ae (extract of French maritime pine bark) for the treatment of\u00a0chronic\u00a0disorders. Cochrane Database Syst Rev. 2012;18(4):CD008294 doi:10.1002\/14651858.CD008294.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"480_CR25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/ptr.3103","volume":"24","author":"E Felixsson","year":"2010","unstructured":"Felixsson E, Persson IA, Eriksson AC, et al. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5\u2011HT(2A) receptors: an in vitro study. Phytother Res. 2010;24:1297\u2013301.","journal-title":"Phytother Res"},{"key":"480_CR26","first-page":"1863","volume":"6","author":"A Lu\u00eds","year":"2011","unstructured":"Lu\u00eds A, Domingues F, Duarte AP. Bioactive compounds, RP-HPLC analysis of phenolics, and antioxidant activity of some Portuguese shrub species extracts. Nat Prod Commun. 2011;6:1863\u201372.","journal-title":"Nat Prod Commun"},{"issue":"11","key":"480_CR27","doi-asserted-by":"publisher","first-page":"CD003230","DOI":"10.1002\/14651858.CD003230.pub4","volume":"14","author":"MH Pittler","year":"2012","unstructured":"Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012;14(11):CD003230 doi:10.1002\/14651858.CD003230.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"480_CR28","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1177\/000331970105202S07","volume":"52","author":"MR Cesarone","year":"2001","unstructured":"Cesarone MR, Incandela L, De Sanctis MT, et al. Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of\u00a0Centella asiatica. Angiology. 2001;52(Suppl 2):S33\u20137.","journal-title":"Angiology"},{"key":"480_CR29","first-page":"229","volume":"10","author":"MR Arpaia","year":"1990","unstructured":"Arpaia MR, Ferrone R, Amitrano M, et\u00a0al. Effects of\u00a0Centella asiatica\u00a0extract on mucopolysaccharide metabolism in subjects with\u00a0varicose veins. Int J Clin Pharmacol Res. 1990;10:229\u201333.","journal-title":"Int J Clin Pharmacol Res"},{"key":"480_CR30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00005344-199901000-00002","volume":"33","author":"D Janssens","year":"1999","unstructured":"Janssens D, Michiels C, Guillaume G, et al. Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. J Cardiovasc Pharmacol. 1999;33:7\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"key":"480_CR31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00005344-199803000-00018","volume":"31","author":"T Arnould","year":"1998","unstructured":"Arnould T, Michiels C, Janssens D, et al. Effect of Ginkor Fort on hypoxia-induced neutrophil adherence to human saphenous vein endothelium. J Cardiovasc Pharmacol. 1998;31:456\u201363.","journal-title":"J Cardiovasc Pharmacol"},{"key":"480_CR32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1055\/s-0031-1280448","volume":"78","author":"O Romero-Cerecero","year":"2012","unstructured":"Romero-Cerecero O, Zamilpa-\u00c1lvarez A, Jim\u00e9nez-Ferrer E, et al. Exploratory study on the effectiveness of a standardized extract from Ageratina pichinchensis in patients with chronic venous leg ulcers. Planta Med. 2012;78:304\u201310.","journal-title":"Planta Med"},{"issue":"Suppl 1","key":"480_CR33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1258\/phleb.2010.010s06","volume":"25","author":"MS Gohel","year":"2010","unstructured":"Gohel MS, Davies AH. Pharmacological treatment in patients with C4, C5 and C6 venous disease. Phlebology. 2010;25(Suppl 1):35\u201341.","journal-title":"Phlebology"},{"key":"480_CR34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0306-3623(98)00040-8","volume":"31","author":"T Tejerina","year":"1998","unstructured":"Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol. 1998;31:357\u201360.","journal-title":"Gen Pharmacol"},{"key":"480_CR35","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/sj.bjp.0701512","volume":"122","author":"C Suschek","year":"1997","unstructured":"Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol. 1997;122:1502\u20138.","journal-title":"Br J Pharmacol"},{"key":"480_CR36","first-page":"124","volume":"21","author":"NB Piller","year":"1988","unstructured":"Piller NB. The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology. 1988;21:124\u20137.","journal-title":"Lymphology"},{"key":"480_CR37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2011.06.015","volume":"667","author":"J Angulo","year":"2011","unstructured":"Angulo J, Peir\u00f3 C, Romacho T, Fern\u00e1ndez A, et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by\u00a0dobesilate. Eur J Pharmacol. 2011;667:153\u20139.","journal-title":"Eur J Pharmacol"},{"key":"480_CR38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1258\/phleb.2010.010052","volume":"26","author":"O Alda","year":"2011","unstructured":"Alda O, Valero MS, Pereboom D, et\u00a0al. In vitro effect of\u00a0calcium dobesilate\u00a0on oxidative\/inflammatory stress in human varicose\u00a0veins. Phlebology. 2011;26:332\u20137.","journal-title":"Phlebology"},{"key":"480_CR39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1024\/0301-1526.37.3.233","volume":"37","author":"E Iriz","year":"2008","unstructured":"Iriz E, Vural C, Ereren E, et al. Effects of\u00a0calcium dobesilate\u00a0and diosmin-hesperidin on apoptosis of venous wall in primary\u00a0varicose\u00a0veins. Vasa. 2008;37:233\u201340.","journal-title":"Vasa"},{"key":"480_CR40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejvs.2007.08.012","volume":"35","author":"MJ Mart\u00ednez-Zapata","year":"2008","unstructured":"Mart\u00ednez-Zapata MJ, Moreno RM, Gich I, et al. A\u00a0randomized,\u00a0double-blind\u00a0multicentre\u00a0clinical\u00a0trial\u00a0comparing\u00a0the\u00a0efficacy\u00a0of\u00a0calcium\u00a0dobesilate\u00a0with placebo\u00a0in the\u00a0treatmentof\u00a0chronic\u00a0venous\u00a0disease. Eur J Vasc Endovasc Surg. 2008;35:358\u201365.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"480_CR41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1258\/phleb.2010.010051","volume":"26","author":"E Rabe","year":"2011","unstructured":"Rabe E, Jaeger KA, Bulitta M, et al. Calcium dobesilate\u00a0in patients suffering from chronic\u00a0venous\u00a0insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology. 2011;26:162\u20138.","journal-title":"Phlebology"},{"key":"480_CR42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1258\/phleb.2009.008085","volume":"25","author":"B Akbulut","year":"2010","unstructured":"Akbulut B. Calcium dobesilate\u00a0and oxerutin: effectiveness of combination therapy. Phlebology. 2010;25:66\u201371.","journal-title":"Phlebology"},{"key":"480_CR43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","volume":"165","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Vidal X, Ballar\u00edn E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869\u201374.","journal-title":"Arch Intern Med"},{"key":"480_CR44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gut.50.2.241","volume":"50","author":"C Raetsch","year":"2002","unstructured":"Raetsch C, Jia JD, Boigk G, et\u00a0al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50:241\u20137.","journal-title":"Gut"},{"key":"480_CR45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cbf.922","volume":"19","author":"PS Bahra","year":"2001","unstructured":"Bahra PS, Rainger GE, Wautier JL, et\u00a0al. Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. Cell Biochem Funct. 2001;19:249\u201357.","journal-title":"Cell Biochem Funct"},{"key":"480_CR46","doi-asserted-by":"crossref","unstructured":"Maessen-Visch MB, de Roos KP. Dutch\u00a0Venous\u00a0Ulcer\u00a0guideline\u00a0update. Phlebology 2014; 29(1 suppl): 153\u2013156.","DOI":"10.1177\/0268355514529693"},{"issue":"12","key":"480_CR47","doi-asserted-by":"publisher","first-page":"CD001733","DOI":"10.1002\/14651858.CD001733.pub3","volume":"12","author":"AB Jull","year":"2012","unstructured":"Jull AB, Arroll B, Parag V, et\u00a0al. Pentoxifylline\u00a0for treating\u00a0venous\u00a0leg ulcers. Cochrane Database Syst Rev. 2012;12(12):CD001733 doi:10.1002\/14651858.CD001733.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"480_CR48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0168-8278(87)80039-9","volume":"5","author":"G Babany","year":"1987","unstructured":"Babany G, Larrey D, Pessayre D, et\u00a0al. Chronic active hepatitis caused by benzarone. J\u00a0Hepatol. 1987;5:332\u20135.","journal-title":"J Hepatol"},{"key":"480_CR49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0676.1995.tb00102.x","volume":"15","author":"ML Hautekeete","year":"1995","unstructured":"Hautekeete ML, Henrion J, Naegels S, et\u00a0al. Severe hepatotoxicity related to\u00a0benzarone: a report of three cases with two fatalities. Liver. 1995;15:25\u20139.","journal-title":"Liver"},{"key":"480_CR50","first-page":"429","volume":"32","author":"R Winand","year":"1977","unstructured":"Winand R. Beta-naphthoquinone mono-semicarbarzone-2 (DCI\u00a0naftazone) in varicose disease [in French. Rev Med Liege. 1977;32:429\u201331.","journal-title":"Rev Med Liege"},{"key":"480_CR51","first-page":"187","volume":"37","author":"C Klein-Soyer","year":"1995","unstructured":"Klein-Soyer C, Bloy C, Archipoff G, et al. Naftazone\u00a0accelerates human saphenous vein endothelial cell proliferation in vitro. Nouv Rev Fr Hematol. 1995;37:187\u201392.","journal-title":"Nouv Rev Fr Hematol"},{"key":"480_CR52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1043-6618(05)80015-5","volume":"32","author":"AM Agha","year":"1995","unstructured":"Agha AM, Gad MZ. Lipid peroxidation and lysosomal integrity in different inflammatory models in rats: the effects of indomethacin and\u00a0naftazone. Pharmacol Res. 1995;32:279\u201385.","journal-title":"Pharmacol Res"},{"key":"480_CR53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(97)01567-7","volume":"344","author":"P Sogni","year":"1998","unstructured":"Sogni P, Yang S, Pilette C, et\u00a0al. Acute and chronic haemodynamic effects of\u00a0naftazone\u00a0in portal hypertensive rats. Eur J Pharmacol. 1998;344:37\u201343.","journal-title":"Eur J Pharmacol"},{"key":"480_CR54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09537109976383","volume":"10","author":"L McGregor","year":"1999","unstructured":"McGregor L, Chignier E, Bloy C, et\u00a0al. Effect of\u00a0naftazone\u00a0on in vivo platelet function in the rat. Platelets. 1999;10:66\u201370.","journal-title":"Platelets"},{"key":"480_CR55","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.2042-7158.1996.tb05975.x","volume":"48","author":"P Durand","year":"1996","unstructured":"Durand P, Bloy C, Peltier-Pujol F, et al. In-vitro and ex-vivo inhibition of blood platelet aggregation by\u00a0naftazone. J\u00a0Pharm Pharmacol. 1996;48:566\u201372.","journal-title":"J Pharm Pharmacol"},{"key":"480_CR56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1472-8206.2011.00951.x","volume":"26","author":"O Rascol","year":"2012","unstructured":"Rascol O, Ferreira J, N\u00e8gre-Pages L, et al. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone\u00a0in Parkinson\u2019s disease. Fundam Clin Pharmacol. 2012;26:557\u201364.","journal-title":"Fundam Clin Pharmacol"},{"key":"480_CR57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1258\/phleb.2007.007054","volume":"23","author":"JM Pereira de Godoy","year":"2008","unstructured":"Pereira de Godoy JM. Aminaphtone in idiopathic cyclic oedema syndrome. Phlebology. 2008;23:118\u20139.","journal-title":"Phlebology"},{"key":"480_CR58","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.clinthera.2008.05.009","volume":"30","author":"R Scorza","year":"2008","unstructured":"Scorza R, Santaniello A, Salazar G, et al. Effects of\u00a0aminaftone\u00a075 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis. Clin Ther. 2008;30:924\u20139.","journal-title":"Clin Ther"},{"key":"480_CR59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00126839-200809040-00005","volume":"9","author":"R Scorza","year":"2008","unstructured":"Scorza R, Santaniello A, Salazar G, et al. Aminaftone, a derivative of 4\u2011aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in vitro Study. Drugs R D. 2008;9:251\u20137.","journal-title":"Drugs R D"},{"key":"480_CR60","first-page":"251","volume":"37","author":"D Anna De","year":"1989","unstructured":"De Anna D, Mari F, Intini S, et\u00a0al. Effects of therapy with\u00a0aminaftone\u00a0on chronic venous and lymphatic stasis. [in Italian. Minerva Cardioangiol. 1989;37:251\u20134.","journal-title":"Minerva Cardioangiol"},{"key":"480_CR61","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0268355513489550","volume":"29","author":"SQ Belczak","year":"2014","unstructured":"Belczak SQ, Sincos IR, Campos W, et al. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2014;29:454\u201360.","journal-title":"Phlebology"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0480-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-016-0480-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0480-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T18:17:13Z","timestamp":1568139433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-016-0480-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":61,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1007\/s10354-016-0480-z","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}